Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > COVID-19 indication
View:
Post by ScienceFirst on Jul 25, 2022 12:04pm

COVID-19 indication

We don't know much about the specifics of our COVID-19 vaccine but we know that we're working with the top scientists within the Special Pathogens group of NML.  

So right there, we seem to be able to fulfill a need that has not been answered by the market so far and that's what interests NML. 

So we would have interested big pharmas, given the credibility of NML.  

The fact that this would be the same molecule (TLD1433) than for oncology should spark curiosity/interest from big pharmas.

Comment by Rumpl3StiltSkin on Jul 25, 2022 2:07pm
As a US guy I know that the curret mRNA vaxx send the spike proteens system wide, nasty stuff. So is the Covid 19 in all it's variants. IMO. the fewer times one is exposed to those spike proteens the better. TLTs vax should avoid that. :-)
Comment by cashworx22 on Jul 25, 2022 2:29pm
This post has been removed in accordance with Community Policy
Comment by thadeush on Jul 25, 2022 2:43pm
There is no evidence that vaccine-generated spike proteins are harmful. The mRNA vaccines work by teaching our cells how to make a harmless spike protein that triggers an immune response inside our bodies. The body then makes antibodies to help you fight infection if the COVID-19 virus enters your body. Some people are concerned that the spike proteins generated by COVID-19 vaccines can cause harm ...more  
Comment by stocksnbonds458 on Jul 25, 2022 2:50pm
Thanks Pfizer, but I will go with Malones's take on spike proteins.
Comment by Rumpl3StiltSkin on Jul 25, 2022 3:04pm
Ok, I agree. There is no evidence, yet... But I wouldn't want to find out the hard way some years later....
Comment by Longholder99 on Jul 25, 2022 3:45pm
My anti vaxxer neighbor, relying on his medical background gleaned from years of selling bank mutual funds to old ladies, coupled with his extensive research conducted in online religious chat groups. Told me the spike proteins build up and stick into your heart muscle. More and more every time you are vaxxed. Causing more and more damage over time. So scary when you think about how this vaccine ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250